An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang Zhen, Lin Xia, Huang You, Zhou Jingwei, Yang Shasha, Wei Xinyi, Lai Wenjing, Zhang Xin, Fu Chaomei
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	irritable bowel syndrome Fuzi-Lizhong pill gut microbiota network pharmacology crucial targets Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9fc6e3040d664f43ab91b1d8bf20890e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9fc6e3040d664f43ab91b1d8bf20890e
record_format	dspace
spelling	oai:doaj.org-article:9fc6e3040d664f43ab91b1d8bf20890e2021-12-01T19:28:05ZAn Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome1663-981210.3389/fphar.2021.746923https://doaj.org/article/9fc6e3040d664f43ab91b1d8bf20890e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.746923/fullhttps://doaj.org/toc/1663-9812Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one of the root causes of IBS-D. Fuzi-Lizhong pill (FLZP) is well known for its powerful capacity for treating SYD and has a good clinical effect on IBS-D. However, the mechanism of FLZP on the gut microbiota of IBS-D has not been fully clarified. Our present study aimed to reveal the mechanism of FLZP regulating gut microbiota of IBS-D. The body mass, CCK, MTL, and Bristol fecal character score were used to verify the establishment of the IBS-D model. IL-6, TNF, IL-1β, and IFN-γ were crucial targets screened by network pharmacology and preliminarily verified by ELISA. Eighteen gut microbiota were important for the treatment of IBS-D with FLZP. Bacteroidetes, Blautia, Turicibacter, and Ruminococcus_torques_group were the crucial gut microbiota that FLZP inhibits persistent systemic inflammation in the IBS-D model. Lactobacillus is the crucial gut microbiota that FLZP renovates intestinal immune barrier in the IBS-D model. In summary, FLZP can affect bacterial diversity and community structures in the host and regulate inflammation and immune system to treat IBS-D.Zhang ZhenZhang ZhenLin XiaHuang YouZhou JingweiYang ShashaWei XinyiLai WenjingZhang XinFu ChaomeiFrontiers Media S.A.articleirritable bowel syndromeFuzi-Lizhong pillgut microbiotanetwork pharmacologycrucial targetsTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	irritable bowel syndrome Fuzi-Lizhong pill gut microbiota network pharmacology crucial targets Therapeutics. Pharmacology RM1-950
spellingShingle	irritable bowel syndrome Fuzi-Lizhong pill gut microbiota network pharmacology crucial targets Therapeutics. Pharmacology RM1-950 Zhang Zhen Zhang Zhen Lin Xia Huang You Zhou Jingwei Yang Shasha Wei Xinyi Lai Wenjing Zhang Xin Fu Chaomei An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
description	Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one of the root causes of IBS-D. Fuzi-Lizhong pill (FLZP) is well known for its powerful capacity for treating SYD and has a good clinical effect on IBS-D. However, the mechanism of FLZP on the gut microbiota of IBS-D has not been fully clarified. Our present study aimed to reveal the mechanism of FLZP regulating gut microbiota of IBS-D. The body mass, CCK, MTL, and Bristol fecal character score were used to verify the establishment of the IBS-D model. IL-6, TNF, IL-1β, and IFN-γ were crucial targets screened by network pharmacology and preliminarily verified by ELISA. Eighteen gut microbiota were important for the treatment of IBS-D with FLZP. Bacteroidetes, Blautia, Turicibacter, and Ruminococcus_torques_group were the crucial gut microbiota that FLZP inhibits persistent systemic inflammation in the IBS-D model. Lactobacillus is the crucial gut microbiota that FLZP renovates intestinal immune barrier in the IBS-D model. In summary, FLZP can affect bacterial diversity and community structures in the host and regulate inflammation and immune system to treat IBS-D.
format	article
author	Zhang Zhen Zhang Zhen Lin Xia Huang You Zhou Jingwei Yang Shasha Wei Xinyi Lai Wenjing Zhang Xin Fu Chaomei
author_facet	Zhang Zhen Zhang Zhen Lin Xia Huang You Zhou Jingwei Yang Shasha Wei Xinyi Lai Wenjing Zhang Xin Fu Chaomei
author_sort	Zhang Zhen
title	An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
title_short	An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
title_full	An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
title_fullStr	An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
title_full_unstemmed	An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
title_sort	integrated gut microbiota and network pharmacology study on fuzi-lizhong pill for treating diarrhea-predominant irritable bowel syndrome
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9fc6e3040d664f43ab91b1d8bf20890e
work_keys_str_mv	AT zhangzhen anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhangzhen anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT linxia anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT huangyou anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhoujingwei anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT yangshasha anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT weixinyi anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT laiwenjing anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhangxin anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT fuchaomei anintegratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhangzhen integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhangzhen integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT linxia integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT huangyou integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhoujingwei integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT yangshasha integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT weixinyi integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT laiwenjing integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT zhangxin integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome AT fuchaomei integratedgutmicrobiotaandnetworkpharmacologystudyonfuzilizhongpillfortreatingdiarrheapredominantirritablebowelsyndrome
_version_	1718404645825544192

An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

Ejemplares similares